Health technology firm Compumedics received approval from the US Food and Drug Administration for its Somfit device to be marketed in the US.
USA's home sleep testing market, targeted by Somfit, is estimated at two million studies annually, representing a potential revenue of US$110 million-US$180 million ($165 million to $270 million).
Compumedics plans to capture 10% to 30% of this market within 24 months.
Compumedics, which reported $1.2 million of sales orders following Somfit's commercialisation in Australia, confirmed FY24 revenue guidance above $44 million and EBITDA above $5 million.